SEC Form S-1 filed by Cardio Diagnostics Holdings Inc.
$CDIO
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-powered precision cardiovascular medicine company, today announced it will sponsor and exhibit at the Florida Association of ACOs (FLAACOs) 2024 Annual Fall Conference, taking place in Orlando, FL, from November 20-22, 2024. The conference, hosted at the JW Marriott Orlando Bonnet Creek, brings together healthcare leaders and organizations focused on advancing value-based care models nationwide. At the event, Cardio Diagnostics will demonstrate how its innovative solutions align with ACOs' mission to deliver high-quality, cost-effective healthcare. The Company will showcase its comprehensive cardiovascular clinical solutions and data
Preliminary CMS pricing determination marks a key milestone in gaining broad access to Medicare reimbursement. Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company today announced that the Company's PrecisionCHD and Epi+Gen CHD tests have received preliminary pricing determinations from the Centers for Medicare & Medicaid Services (CMS). This determination represents a crucial step toward securing Medicare reimbursement, enabling access to the Company's affordable, innovative, and highly scalable blood tests aimed at improving the risk assessment, diagnosis, management and monitoring of coronary heart disease (CHD) for Medicare patients.
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), a leader in AI-powered precision cardiovascular medicine, today announced the launch of its redesigned website at CDIO.AI. This new site emphasizes the Company's AI-first approach and innovative scalable solutions for the prevention, detection and management of cardiovascular disease, which is the leading cause of death globally. This site also streamlines access to critical information and resources for investors, partners, patients, providers, and other key stakeholders. The redesigned website provides a significantly enhanced user experience, ensuring that each stakeholder group can easily navigate and find relevant information. Investor
SC 13G/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Subject)
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS, as a Strategic Advisor. Dr. Ramjee is a cardiologist and a health innovation leader, serving as the National Co-Chair of Cardiology and Innovation at CommonSpirit Health Enterprise and is also a member of the American Heart Association Board of Directors. The appointment of Dr. Ramjee as a Strategic Advisor to Cardio Diagnostics is a significant development to the Company's continued growth and market expansion. He brings a wealth of experience and proven track record in clinical practice, innovation and research, makin
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Paul Burton, J.D., MBA to its Board of Directors as an Independent Director. Mr. Burton will Chair the Nominating and Corporate Governance Committee and will also serve as a member of the Audit Committee. Mr. Burton is the Managing Partner at 2Flo Ventures, an early-stage healthcare investor and startup studio focused on accelerating health equity. He is also the CEO of Akan Biosciences, a clinical-stage biotech company, and runs an advisory firm working closely with healthcare growth companies. Mr. Burton brings over 20 years of experience in medical
4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4/A - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
S-1 - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
8-K - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
10-Q - Cardio Diagnostics Holdings, Inc. (0001870144) (Filer)
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
4 - Cardio Diagnostics Holdings, Inc. (0001870144) (Issuer)
Mayumi Kitakata, a 57-year-old resident of Tokyo, Japan, is among the many pet owners who have turned to artificial intelligence to ensure the well-being of their furry companions. What Happened: Kitakata, who is concerned about the health of her 14-year-old cat, Chi, has adopted CatsMe!, an AI-driven smartphone application that claims to detect feline pain, reported Reuters. Kitakata, who has had cats since her mid-20s, uses the app to monitor Chi’s urinal activity and facial expressions. She believes that if she had used CatsMe! with her previous cat, Soran, she might have been able to detect his cancer earlier and potentially save him. See Also: Apple Analyst Says ‘You Don’t Wann